GERMANTOWN, Md., April 29, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and its majority owned Intrexon Health subsidiary Xogenex, today announced that four abstracts will be presented as posters at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, which will be held April 29 - May 2, 2019, at the Washington Hilton in Washington, D.C.
Intrexon Health is dedicated to the development of targeted, controllable, multigenic therapeutics for the treatment of complex diseases and unmet medical needs. During the 2019 ASGCT conference, Dr. Amit Patel (Founder of Xogenex) and Dr. Thomas Reed (Founder and CSO of Intrexon) will introduce scientific details associated with the development of INXN-4001, the world's first triple effector gene drug candidate to treat heart failure.
"I am honored to be joining Dr. Patel as we review the path to the clinic for INXN-4001, a non-viral, multigenic triple effector plasmid designed to address multiple cardiovascular malfunctions in patients with heart failure and currently in a Phase 1 trial," stated Dr. Reed. "This drug candidate exemplifies the Intrexon Health focus, as we're employing a minimally-invasive delivery system to target our transient, non-integrating naked plasmid DNA to the cardiac compartment and using an optimized vector to control the expression and function of multigenic therapeutic effectors. We're grateful to the ASGCT organizers for providing us a unique venue wherein we can present across four posters the details of this exciting program to treat heart failure."
The abstracts being presented on May 1, 2019, between 5 - 6 pm ET in Columbia Hall are as follows:
- First Human Experience with Novel Triple Effector Gene Therapy for Heart Failure – INXN-4001 (Abstract Number 772)
- Retrograde Delivery of Novel Triple Effector pDNA Gene Therapy for Heart Failure (Abstract Number 775)
- Human Cardiac iPSC Evaluation of Novel Triple Effector Gene Therapy for Dilated Cardiomyopathy (Abstract Number 777)
- Minimally Invasive Novel Triple Effector Gene Therapy for Adriamycin Cardiomyopathy (Abstract Number 780)
Preclinical studies described in these posters set the basis for demonstrating safety and clinically relevant findings with INXN-4001 and provided support for translation into the clinical setting. Evaluation of the Phase 1 trial data for three patients reflecting the patients' status six months after being given the INXN-4001 appears to indicate that the drug material and the delivery process were both well-tolerated. Preliminary review of the data suggests that the therapy improved several cardiac performance parameters.
The ASGCT Annual Meeting brings together international scientists, physicians, and patient advocates to present and critically discuss the latest gene and cell therapy developments.
About Intrexon Corporation
Intrexon Corporation (NASDAQ: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet through two operating units – Intrexon Health and Intrexon Bioengineering. Intrexon Health is focused on addressing unmet medical needs through a diverse spectrum of therapeutic modalities, including gene and cell therapies, microbial bioproduction, and regenerative medicine. Intrexon Bioengineering seeks to address global challenges across food, agriculture, environmental, and industrial fields by advancing biologically engineered solutions to improve sustainability and efficiency. Our integrated technology suite provides industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn.
Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.
For more information about Intrexon Corporation, contact:
Vice President, Investor Relations
Tel: +1 (214) 721-0607
Marie Rossi, PhD
Vice President, Communications
Tel: +1 (301) 556-9850
SOURCE Intrexon Corporation